Dennis Ding
Stock Analyst at Jefferies
(n/a)
# 4,857
Out of 4,874 analysts
12
Total ratings
n/a
Success rate
-24.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MLYS Mineralys Therapeutics | Initiates: Hold | $15 | $14.00 | +7.14% | 1 | Jun 11, 2025 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $55 | $29.99 | +83.39% | 1 | Jan 22, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $8 | $1.65 | +384.85% | 1 | Nov 8, 2024 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $2 → $35 | $17.08 | +104.92% | 1 | Sep 20, 2024 | |
| FOLD Amicus Therapeutics | Initiates: Buy | $18 | $5.69 | +216.34% | 1 | Sep 6, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 → $7 | $3.20 | +118.75% | 2 | Sep 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Hold | $8 → $6 | $5.40 | +11.11% | 1 | Sep 3, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Hold | $500 → $25 | $13.38 | +86.85% | 1 | May 7, 2024 | |
| CORT Corcept Therapeutics | Downgrades: Hold | $35 → $22 | $74.33 | -70.40% | 1 | Feb 15, 2023 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Buy | $24 | $18.45 | +30.08% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $11.60 | -13.79% | 1 | Oct 26, 2021 |
Mineralys Therapeutics
Jun 11, 2025
Initiates: Hold
Price Target: $15
Current: $14.00
Upside: +7.14%
Crinetics Pharmaceuticals
Jan 22, 2025
Upgrades: Buy
Price Target: $55
Current: $29.99
Upside: +83.39%
Inhibikase Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $8
Current: $1.65
Upside: +384.85%
Assembly Biosciences
Sep 20, 2024
Upgrades: Buy
Price Target: $2 → $35
Current: $17.08
Upside: +104.92%
Amicus Therapeutics
Sep 6, 2024
Initiates: Buy
Price Target: $18
Current: $5.69
Upside: +216.34%
Arbutus Biopharma
Sep 5, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $3.20
Upside: +118.75%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Hold
Price Target: $8 → $6
Current: $5.40
Upside: +11.11%
Lyra Therapeutics
May 7, 2024
Downgrades: Hold
Price Target: $500 → $25
Current: $13.38
Upside: +86.85%
Corcept Therapeutics
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $74.33
Upside: -70.40%
NewAmsterdam Pharma Company
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $18.45
Upside: +30.08%
Oct 26, 2021
Initiates: Buy
Price Target: $10
Current: $11.60
Upside: -13.79%